170 related articles for article (PubMed ID: 35685767)
1. THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.
Yao Z; Lin A; Yi Y; Shen W; Zhang J; Luo P
Drug Des Devel Ther; 2022; 16():1679-1695. PubMed ID: 35685767
[TBL] [Abstract][Full Text] [Related]
2.
Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
[TBL] [Abstract][Full Text] [Related]
3. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
[No Abstract] [Full Text] [Related]
4. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
5. [Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
Li HM; Yuan P; Yu DK; Ma F; Tan WW; Feng T; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):504-9. PubMed ID: 27531263
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
7. Activation of the TGF-
Lin A; Zhu L; Jiang A; Mou W; Zhang J; Luo P
Dis Markers; 2022; 2022():8766448. PubMed ID: 36590751
[TBL] [Abstract][Full Text] [Related]
8. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
9. CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Yi Y; Qiu Z; Yao Z; Lin A; Qin Y; Sha R; Wei T; Wang Y; Cheng Q; Zhang J; Luo P; Shen W
Front Cell Dev Biol; 2021; 9():770811. PubMed ID: 35087829
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
11. High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
Lyu Q; Zhu W; Wei T; Ding W; Cao M; Wang Q; Guo L; Luo P; Zhang J
Cancer Med; 2021 Nov; 10(21):7863-7876. PubMed ID: 34564955
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
Bandyopadhyay A; Sharma S; Behera D; Singh N
Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
[TBL] [Abstract][Full Text] [Related]
13. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
15. Overcoming Chemotherapy Resistance in SCLC.
Herzog BH; Devarakonda S; Govindan R
J Thorac Oncol; 2021 Dec; 16(12):2002-2015. PubMed ID: 34358725
[TBL] [Abstract][Full Text] [Related]
16. eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer.
Chen YX; Wang CJ; Xiao DS; He BM; Li M; Yi XP; Zhang W; Yin JY; Liu ZQ
Pharmacol Res; 2021 Dec; 174():105934. PubMed ID: 34648968
[TBL] [Abstract][Full Text] [Related]
17. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
Yang Y; Luo X; Yang N; Feng R; Xian L
PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy.
Jin S; Cao S; Xu S; Wang C; Meng Q; Yu Y
Clin Respir J; 2018 Sep; 12(9):2433-2440. PubMed ID: 30074685
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
